"In my view, we have a new standard of care for treatment of BRAF-mutant advanced melanoma," Prof Grant McArthur tells ecancertv at ESMO 2014.

The coBRIM study, a phase III trial examining the effectiveness of combining cobimetinib and vemurafenib to treat advanced melanoma, demonstrated a 49% reduction in the risk of progression or death in patients treated with the combined therapy. 

Watch the press conference and read the news story for more.

ecancer's filming at ESMO has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.